SCHEMBL30129596

SCHEMBL30129596

Cn1cc(C(=O)Nc2ccc(F)c(Cl)c2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.63
MAOA P21397 2/20 0.63
LMNA P02545 2/20 0.60
ALDH1A1 P00352 1/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.58
MAPT P10636 3/20 0.56
DHX9 Q08211 1/20 0.55
KCNQ3 O43525 1/20 0.53
KCNQ2 O43526 1/20 0.53
KCNE1 P15382 1/20 0.53
KCNQ1 P51787 1/20 0.53
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 1/20 0.51
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30216595 0.81 SMN1; SMN2 (0.64) LMNAALDH1A1NPC1RAB9AMAPT
SCHEMBL15875707 0.77 MAOB (1.00) MAOBMAOAALDH1A1NPC1RAB9A
SCHEMBL15875495 0.77 MAOB (1.00) MAOBMAOALMNAALDH1A1NPC1
SCHEMBL13210571 0.76 L3MBTL1 (0.67) MAOBMAOALMNAALDH1A1NPC1
SCHEMBL17803491 0.75 NPC1 (0.68) MAOBMAOALMNANPC1RAB9A
SCHEMBL2679067 0.75 NPC1 (0.73) MAOBMAOALMNAALDH1A1NPC1
SCHEMBL374330 0.75 DHX9 (0.65) MAOALMNAALDH1A1NPC1RAB9A
SCHEMBL24934054 0.75 DHX9 (0.69) LMNAALDH1A1NPC1RAB9AMAPT
SCHEMBL14917101 0.75 DHX9 (0.69) LMNAALDH1A1NPC1RAB9AMAPT
SCHEMBL23931167 0.74 KMT2A (0.55) MAOBMAOALMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV ASSEMBLY BIOSCIENCES, INC. 2024-05-09 US disclosed
CN-115916341-A Pyrazole carboxamide compounds for the treatment of HBV 组装生物科学股份有限公司 2023-04-04 CN disclosed
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV ASSEMBLY BIOSCIENCES, INC. (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560370-B1 5-membered heteroaryl carboxamide compounds for treatment of HBV HCCS, HAVCR2, MAVS MAOB 4219/4885MAOA 4429/4885LMNA 1876/4885
US-20240150324-A1 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV HCCS, HAVCR2, MAVS MAOB 4219/4885MAOA 4429/4885LMNA 1876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.